Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun An
immunosuppressant , asemisynthetic derivative ofrapamycin .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word zotarolimus.
Examples
-
Background New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis.
-
Methods In this multicenter, noninferiority trial with minimal exclusion criteria, we randomly assigned 2292 patients to undergo treatment with coronary stents releasing either zotarolimus or everolimus.
-
The zotarolimus-eluting stent was noninferior to the everolimus-eluting stent with respect to the primary end point, which occurred in 8.2% and 8.3% of were no significant between-group differences in the rate of death from cardiac causes, any myocardial infarction, or revascularization.
-
The zotarolimus-eluting stent was also noninferior regarding the degree (±SD) of in-stent stenosis (21. 65±14.42% for zotarolimus vs. 19. 76±14.64% for everolimus, P = 0.04 for noninferiority).
-
At 13 months, the new-generation zotarolimus-eluting stent was found to be noninferior to the everolimus-eluting stent in a population of patients who had minimal exclusion
-
The rate of stent thrombosis was 2.3% in the zotarolimus-stent group and 1.5% in the everolimus-stent group (P = 0.17).
-
In-stent late lumen loss was 0. 27±0.43 mm in the zotarolimus-stent group versus 0. 19±0.40 mm in the everolimus-stent group
-
Endeavor zotarolimus-eluting coronary stent gets market green light
-
Coupled with the MicroTrac delivery system, continuous sinusoid technology improves deliverability without compromising other important stent's conformability - the ability of the stent to conform to the natural shape of the vessel and maintain apposition to the vessel wall after inflation with the balloon drug-eluting stents to address the spectrum of clinical need for patients with drug-eluting stent (DES) combines continuous sinusoid technology with two key elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer.
-
Coupled with the MicroTrac delivery system, continuous sinusoid technology improves deliverability without compromising other important stent's conformability - the ability of the stent to conform to the natural shape of the vessel and maintain apposition to the vessel wall after inflation with the balloon drug-eluting stents to address the spectrum of clinical need for patients with drug-eluting stent (DES) combines continuous sinusoid technology with two key elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.